Rutherford Bret R, Wall Melanie M, Glass Andrew, Stewart Jonathan W
Columbia University College of Physicians and Surgeons, Department of Psychiatry, New York State Psychiatric Institute, 1051 Riverside Drive, Box 98, New York, NY 10032
J Clin Psychiatry. 2014 Oct;75(10):1040-6. doi: 10.4088/JCP.13m08797.
To determine whether patient expectancy plays a role in observed placebo and nocebo effects in 2 clinical trials.
Data were reanalyzed from 2 fluoxetine-discontinuation studies conducted from March 1990 to September 1992 and from May 1997 to December 2002. The 673 outpatients included were aged 18-65 years with DSM-III-R major depressive disorder (MDD), responded to 12-week duration open treatment, and were randomized to continued fluoxetine or placebo for an additional year. Participants in 1 of the included studies received a fixed dose of fluoxetine 20 mg daily, while the second study utilized flexible fluoxetine doses up to 60 mg daily. Mixed effects longitudinal models determined whether the possible randomization to placebo at 12 weeks resulted in significant depressive symptom worsening across treatments. Correlations were computed between early symptom change (weeks 1-3 of open treatment) and postrandomization symptom change (weeks 13-16 following randomization).
Participants continuing to receive fluoxetine and those switched to placebo had significantly higher mean Hamilton Depression Rating Scale (HDRS) scores immediately postrandomization compared to the final weeks of open treatment (P < .001 for both fluoxetine- and placebo-treated patients). In both studies, early HDRS change was significantly correlated with postrandomization HDRS change for patients receiving fluoxetine (r = -0.46, P < .001) as well as placebo (r = -0.48, P < .001).
The possibility of receiving placebo following 12 weeks of open fluoxetine was associated with significant symptom worsening in 2 large fluoxetine discontinuation studies. Worsening depression scores following randomization were significantly associated with the degree of improvement participants experienced during weeks 1-3 of open treatment. These results suggest that treatment changes influence patients' expectations of improvement, which, in turn, affect their depressive symptoms.
在两项临床试验中确定患者期望是否在观察到的安慰剂和反安慰剂效应中起作用。
对1990年3月至1992年9月以及1997年5月至2002年12月进行的两项氟西汀停药研究的数据进行重新分析。纳入的673名门诊患者年龄在18 - 65岁,患有DSM-III-R重度抑郁症(MDD),对为期12周的开放治疗有反应,并被随机分配继续使用氟西汀或安慰剂再治疗一年。其中一项纳入研究的参与者每天接受固定剂量20毫克的氟西汀,而第二项研究使用了高达每天60毫克的灵活氟西汀剂量。混合效应纵向模型确定在12周时随机分配到安慰剂组是否会导致各治疗组的抑郁症状显著恶化。计算开放治疗早期症状变化(第1 - 3周)与随机分组后症状变化(随机分组后第13 - 16周)之间的相关性。
与开放治疗的最后几周相比,继续接受氟西汀治疗的参与者和改用安慰剂治疗的参与者在随机分组后立即的汉密尔顿抑郁量表(HDRS)平均得分显著更高(氟西汀治疗组和安慰剂治疗组患者均P < 0.001)。在两项研究中,接受氟西汀治疗的患者(r = -0.46,P < 0.001)以及接受安慰剂治疗的患者(r = -0.48,P < 0.001),其早期HDRS变化与随机分组后HDRS变化均显著相关。
在两项大型氟西汀停药研究中,接受12周开放氟西汀治疗后可能接受安慰剂与显著的症状恶化相关。随机分组后抑郁评分恶化与参与者在开放治疗第1 - 3周所经历的改善程度显著相关。这些结果表明治疗变化会影响患者对改善的期望,进而影响他们的抑郁症状。